Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxymetazoline Cream vs Rhofade in Rosacea
NCT03954444Phase 3Completed
- Sponsor
- Allergan
- Start
- Apr 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AGN-199201 in rosacea (3 arms), sponsored by Allergan. Primary endpoint: Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Started Apr 2019; status: completed.
02
Drugs
AGN-199201
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT03954444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03954444.